ELV SEC filings (2026)
CIK 1156039 · Hospital & Medical Service Plans (SIC 6324) · incorporated in IN · fiscal year ends in December
2,624 filings on EDGAR since 2001 · 25 annual, 78 quarterly, 390 current · financial statements · earnings
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
October 2026
- Oct 21ReportQuarterly report, Q3 2026 — revenue $51.43B (+1% y/y), net income $1.36B, EPS $6.27
- Oct 218-K8-K · ELEVANCE HEALTH REPORTS THIRD QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCEResults of operations
September 2026
- Sep 108-K8-K · Regulation FD disclosure
July 2026
- Jul 17Insider buyBOUDREAUX GAIL (President and CEO · Director) bought 2,725 shares for $1.0M at $366.41–$368.25
- Jul 17Insider buyPERU RAMIRO G (Director) bought 1,000 shares for $366K at $366.05
- Jul 15EarningsEarnings release — EPS $7.45 vs $6.18 est. (+20.6%); revenue $50.47B (+1% y/y) 8.5%
- Jul 15ReportQuarterly report, Q2 2026 — revenue $50.47B (+1% y/y), net income $1.46B, EPS $6.71
June 2026
- Jun 12Insider salePenczek Ronald W (CAO & Controller) sold 369 shares for $149K at $403.16
- Jun 11Insider saleDixon Robert L JR (Director) sold 151 shares for $61K at $401.77
- Jun 108-K8-K · Regulation FD disclosure
May 2026
- May 19Insider salePenczek Ronald W (CAO & Controller) sold 1,531 shares for $617K at $403.13
- May 138-K8-K · Shareholder vote results
April 2026
- Apr 22EarningsEarnings release — EPS $12.58 vs $10.68 est. (+17.8%); revenue $50.18B (+3% y/y) 0.0%
- Apr 22ReportQuarterly report, Q1 2026 — revenue $50.18B (+3% y/y), net income $1.76B, EPS $8.00
- Apr 7ProxyProxy · Shareholder exempt solicitation
March 2026
- Mar 27ProxyProxy · Additional proxy materials
- Mar 27ProxyProxy · Proxy statement
- Mar 12Insider saleSCHULMAN AMY W (Director) sold 26 shares for $7,475 at $287.50
- Mar 108-K8-K · Regulation FD disclosure
- Mar 6Insider saleKendrick Charles Morgan JR (EVP & President, Commercial) sold 3,196 shares for $911K at $284.92
- Mar 5Insider buyCOLLIS STEVEN H (Director) bought 3,000 shares for $870K at $289.84
- Mar 28-K8-K · Other events
February 2026
- Feb 268-K8-K · Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits OrganizationDirectors or officers; compensation; Regulation FD disclosure
- Feb 6ReportAnnual report, FY2025 — revenue $199.13B (+12% y/y), net income $5.66B, EPS $25.21
January 2026
December 2025
- Dec 108-K8-K · Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance ExcellenceDirectors or officers; compensation
November 2025
- Nov 108-K8-K · Regulation FD disclosure
October 2025
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $1.7M in 5 sales and bought $2.2M in 3 purchases; 53 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Jul 17, 2026Form 4 | BOUDREAUX GAILPresident and CEO · DirectorBought · $1.0M · 2,725 sh |
| Jul 17, 2026Form 4 | PERU RAMIRO GDirectorBought · $366K · 1,000 sh |
| Jun 12, 2026Form 4 | Penczek Ronald WCAO & ControllerSold · $149K · 369 sh |
| Jun 11, 2026Form 4 | Dixon Robert L JRDirectorSold · $61K · 151 sh |
| May 19, 2026Form 4 | Penczek Ronald WCAO & ControllerSold · $617K · 1,531 sh |
| Mar 12, 2026Form 4 | SCHULMAN AMY WDirectorSold · $7,475 · 26 sh |
| Mar 6, 2026Form 4 | Kendrick Charles Morgan JREVP & President, CommercialSold · $911K · 3,196 sh |
| Mar 5, 2026Form 4 | COLLIS STEVEN HDirectorBought · $870K · 3,000 sh |
Awards, exercises, withholding and plan purchases · 53 transactions
| Date | Insider |
|---|---|
| Oct 2, 2026Form 4 | Kaye MarkEVP & CFOTax withholding · $1.6M · 4,161 sh |
| Oct 2, 2026Form 4 | Kaye MarkEVP & CFOAward · $0 · 2,627 sh |
| Sep 3, 2026Form 4 | Wessling Erin MEVP & Chief Legal OfficerTax withholding · $106K · 255 sh |
| Sep 2, 2026Form 4 | Craig Ryan REVP & Chief HR OfficerTax withholding · $58K · 144 sh |
| Sep 2, 2026Form 4 | Wessling Erin MEVP & Chief Legal OfficerTax withholding · $38K · 94 sh |
| May 19, 2026Form 4 | Penczek Ronald WCAO & ControllerExercise or conversion · $451K · 1,531 sh |
| May 19, 2026Form 4 | Penczek Ronald WCAO & ControllerExercise or conversion · Employee Stock Option (Rig… · $0 · 1,531 sh |
| May 13, 2026Form 4 | HAY LEWIS IIIDirectorAward · $0 · 563 sh |
| May 13, 2026Form 4 | COLLIS STEVEN HDirectorAward · $0 · 563 sh |
| May 13, 2026Form 4 | PERU RAMIRO GDirectorAward · $0 · 563 sh |
| May 13, 2026Form 4 | Schneider Ryan M.DirectorAward · $0 · 563 sh |
| May 13, 2026Form 4 | SCHULMAN AMY WDirectorAward · $0 · 563 sh |
| May 13, 2026Form 4 | Dixon Robert L JRDirectorAward · $0 · 563 sh |
| May 13, 2026Form 4 | DeVore Susan D.DirectorAward · $0 · 563 sh |
| May 13, 2026Form 4 | STRABLE-SOETHOUT DEANNA DDirectorAward · $0 · 563 sh |
| May 13, 2026Form 4 | Neri Antonio FDirectorAward · $0 · 563 sh |
| May 13, 2026Form 4 | Jallal BahijaDirectorAward · $0 · 563 sh |
| Mar 3, 2026Form 4 | BOUDREAUX GAILPresident and CEO · DirectorTax withholding · $493K · 1,736 sh |
| Mar 3, 2026Form 4 | Norwood Felicia FEVP &Chief Health Benefits OfrTax withholding · $141K · 496 sh |
| Mar 3, 2026Form 4 | Kendrick Charles Morgan JREVP & President, CommercialTax withholding · $133K · 467 sh |
| Mar 3, 2026Form 4 | Haytaian Peter DEVP & Pres Carelon & CarelonRxTax withholding · $127K · 446 sh |
| Mar 3, 2026Form 4 | Wessling Erin MEVP & Chief Legal OfficerTax withholding · $118K · 417 sh |
| Mar 3, 2026Form 4 | Kaye MarkEVP & CFOTax withholding · $100K · 353 sh |
| Mar 3, 2026Form 4 | Craig Ryan REVP & Chief HR OfficerTax withholding · $88K · 309 sh |
| Mar 3, 2026Form 4 | LAVU RATNAKAREVP & Chief Digital Info OfrTax withholding · $63K · 222 sh |
| Mar 3, 2026Form 4 | Penczek Ronald WCAO & ControllerTax withholding · $11K · 37 sh |
| Mar 2, 2026Form 4 | BOUDREAUX GAILPresident and CEO · DirectorTax withholding · $2.0M · 6,713 sh |
| Mar 2, 2026Form 4 | Norwood Felicia FEVP &Chief Health Benefits OfrTax withholding · $418K · 1,421 sh |
| Mar 2, 2026Form 4 | Kendrick Charles Morgan JREVP & President, CommercialTax withholding · $356K · 1,211 sh |
| Mar 2, 2026Form 4 | Haytaian Peter DEVP & Pres Carelon & CarelonRxTax withholding · $353K · 1,201 sh |
| Mar 2, 2026Form 4 | LAVU RATNAKAREVP & Chief Digital Info OfrTax withholding · $93K · 315 sh |
| Mar 2, 2026Form 4 | Kaye MarkEVP & CFOTax withholding · $80K · 271 sh |
| Mar 2, 2026Form 4 | Penczek Ronald WCAO & ControllerTax withholding · $39K · 131 sh |
| Mar 2, 2026Form 4 | Craig Ryan REVP & Chief HR OfficerTax withholding · $7,352 · 25 sh |
| Mar 2, 2026Form 4 | BOUDREAUX GAILPresident and CEO · DirectorAward · Employee Stock Option (Rig… · $0 · 63,818 sh |
| Mar 2, 2026Form 4 | BOUDREAUX GAILPresident and CEO · DirectorAward · $0 · 26,680 sh |
| Mar 2, 2026Form 4 | Kaye MarkEVP & CFOAward · Employee Stock Option (Rig… · $0 · 25,188 sh |
| Mar 2, 2026Form 4 | Norwood Felicia FEVP &Chief Health Benefits OfrAward · Employee Stock Option (Rig… · $0 · 23,512 sh |
| Mar 2, 2026Form 4 | LAVU RATNAKAREVP & Chief Digital Info OfrAward · Employee Stock Option (Rig… · $0 · 20,152 sh |
| Mar 2, 2026Form 4 | Kaye MarkEVP & CFOAward · $0 · 16,579 sh |
| Mar 2, 2026Form 4 | Kendrick Charles Morgan JREVP & President, CommercialAward · Employee Stock Option (Rig… · $0 · 15,870 sh |
| Mar 2, 2026Form 4 | LAVU RATNAKAREVP & Chief Digital Info OfrAward · $0 · 11,903 sh |
| Mar 2, 2026Form 4 | Craig Ryan REVP & Chief HR OfficerAward · Employee Stock Option (Rig… · $0 · 11,754 sh |
| Mar 2, 2026Form 4 | Wessling Erin MEVP & Chief Legal OfficerAward · Employee Stock Option (Rig… · $0 · 11,754 sh |
| Mar 2, 2026Form 4 | Norwood Felicia FEVP &Chief Health Benefits OfrAward · $0 · 8,816 sh |
| Mar 2, 2026Form 4 | Kendrick Charles Morgan JREVP & President, CommercialAward · $0 · 6,549 sh |
| Mar 2, 2026Form 4 | Craig Ryan REVP & Chief HR OfficerAward · $0 · 2,976 sh |
| Mar 2, 2026Form 4 | Wessling Erin MEVP & Chief Legal OfficerAward · $0 · 2,976 sh |
| Mar 2, 2026Form 4 | Haytaian Peter DEVP & Pres Carelon & CarelonRxAward · $0 · 2,865 sh |
| Mar 2, 2026Form 4 | Penczek Ronald WCAO & ControllerAward · $0 · 2,393 sh |
| Mar 2, 2026Form 4 | Penczek Ronald WCAO & ControllerAward · Employee Stock Option (Rig… · $0 · 1,677 sh |
| Feb 2, 2026Form 4 | Craig Ryan REVP & Chief HR OfficerTax withholding · $95K · 279 sh |
| Feb 2, 2026Form 4 | SCHULMAN AMY WDirectorAward · $0 · 218 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.
2026 · 17 filings
| Filed | What it is |
|---|---|
| Oct 21, 202610-Q | Quarterly report, Q3 2026 — revenue $51.43B (+1% y/y), net income $1.36B, EPS $6.27 |
| Oct 21, 20268-K | ELEVANCE HEALTH REPORTS THIRD QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCEResults of operations |
| Sep 10, 20268-K | Regulation FD disclosure |
| Jul 15, 202610-Q | Quarterly report, Q2 2026 — revenue $50.47B (+1% y/y), net income $1.46B, EPS $6.71 |
| Jul 15, 20268-K | Earnings release — EPS $7.45 vs $6.18 est. (+20.6%); revenue $50.47B (+1% y/y) 8.5% |
| Jun 10, 20268-K | Regulation FD disclosure |
| May 13, 20268-K | Shareholder vote results |
| Apr 22, 202610-Q | Quarterly report, Q1 2026 — revenue $50.18B (+3% y/y), net income $1.76B, EPS $8.00 |
| Apr 22, 20268-K | Earnings release — EPS $12.58 vs $10.68 est. (+17.8%); revenue $50.18B (+3% y/y) 0.0% |
| Apr 7, 2026PX14A6G | Shareholder exempt solicitation |
| Mar 27, 2026DEFA14A | Additional proxy materials |
| Mar 27, 2026DEF 14A | Proxy statement |
| Mar 10, 20268-K | Regulation FD disclosure |
| Mar 2, 20268-K | Other events |
| Feb 26, 20268-K | Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits OrganizationDirectors or officers; compensation; Regulation FD disclosure |
| Feb 6, 202610-K | Annual report, FY2025 — revenue $199.13B (+12% y/y), net income $5.66B, EPS $25.21 |
| Jan 28, 20268-K | Earnings release — EPS $3.33 vs $3.10 est. (+7.4%); revenue $49.75B (+9% y/y) 5.9% |
2025 · 21 filings
| Filed | What it is |
|---|---|
| Dec 10, 20258-K | Elevance Health Board Welcomes Amy Schulman as New Director, Reflecting Ongoing Commitment to Governance ExcellenceDirectors or officers; compensation |
| Nov 10, 20258-K | Regulation FD disclosure |
| Oct 21, 202510-Q | Quarterly report, Q3 2025 — revenue $50.71B (+12% y/y), net income $1.19B, EPS $5.32 |
| Oct 21, 20258-K | Earnings release — EPS $6.03 vs $4.98 est. (+21.1%); revenue $50.71B (+12% y/y) 1.2% |
| Sep 15, 20258-K | Other events |
| Sep 4, 20258-K | Regulation FD disclosure |
| Jul 28, 20258-K | Directors or officers; compensation |
| Jul 17, 202510-Q | Quarterly report, Q2 2025 — revenue $49.78B (+13% y/y), net income $1.74B, EPS $7.72 |
| Jul 17, 20258-K | Earnings release — EPS $8.84 vs $9.16 est. (−3.5%); revenue $49.78B (+13% y/y) 12.2% |
| May 28, 20258-K | Regulation FD disclosure |
| May 14, 20258-K | Shareholder vote results |
| Apr 22, 202510-Q | Quarterly report, Q1 2025 — revenue $48.89B (+15% y/y), net income $2.18B, EPS $9.61 |
| Apr 22, 20258-K | Earnings release — EPS $11.97 vs $11.97 est.; revenue $48.89B (+15% y/y) 2.3% |
| Apr 17, 20258-K | Results of operations; Regulation FD disclosure |
| Apr 14, 2025PX14A6G | Shareholder exempt solicitation |
| Mar 28, 2025DEFA14A | Additional proxy materials |
| Mar 28, 2025DEFA14A | Additional proxy materials |
| Mar 28, 2025DEF 14A | Proxy statement |
| Mar 10, 20258-K | Regulation FD disclosure |
| Feb 20, 202510-K | Annual report, FY2024 — revenue $177.01B (+3% y/y), net income $5.98B, EPS $25.68 |
| Jan 23, 20258-K | Earnings release — EPS $3.84 vs $3.80 est. (+1.1%); revenue $45.44B (+7% y/y) 2.7% |
2024 · 17 filings
| Filed | What it is |
|---|---|
| Oct 31, 20248-K | Other events |
| Oct 17, 202410-Q | Quarterly report, Q3 2024 — revenue $45.11B (+5% y/y), net income $1.02B, EPS $4.36 |
| Oct 17, 20248-K | Earnings release — EPS $8.37 vs $9.70 est. (−13.7%); revenue $45.11B (+5% y/y) 10.6% |
| Jul 17, 202410-Q | Quarterly report, Q2 2024 — revenue $43.89B (+0% y/y), net income $2.30B, EPS $9.85 |
| Jul 17, 20248-K | Earnings release — EPS $10.12 vs $9.99 est. (+1.3%); revenue $43.89B (+0% y/y) 5.8% |
| Jun 12, 20248-K | Regulation FD disclosure |
| May 30, 20248-K | Other events |
| May 15, 20248-K | Shareholder vote results |
| Apr 22, 2024DEFA14A | Additional proxy materials |
| Apr 18, 202410-Q | Quarterly report, Q1 2024 — revenue $42.58B (+1% y/y), net income $2.25B, EPS $9.59 |
| Apr 18, 20248-K | Earnings release — EPS $10.64 vs $10.54 est. (+0.9%); revenue $42.58B (+1% y/y) 3.2% |
| Mar 29, 2024DEFA14A | Additional proxy materials |
| Mar 29, 2024DEF 14A | Proxy statement |
| Mar 4, 20248-K | Regulation FD disclosure |
| Feb 21, 202410-K | Annual report, FY2023 — revenue $171.34B (+9% y/y), net income $5.99B, EPS $25.22 |
| Jan 25, 20248-K | Other events |
| Jan 24, 20248-K | Earnings release — EPS $5.62 vs $5.55 est. (+1.3%); revenue $42.65B (+7% y/y) 0.3% |
2023 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Oct 18, 202310-Q | Quarterly report, Q3 2023 — revenue $42.85B (+7% y/y), net income $1.29B, EPS $5.45 |
| Sep 29, 202310-Q/A | Quarterly report, amended |
| Jul 19, 202310-Q | Quarterly report |
| Apr 19, 202310-Q | Quarterly report, Q1 2023 — revenue $42.17B (+11% y/y), net income $1.99B, EPS $8.30 |
| Mar 31, 2023DEFA14A | Additional proxy materials |
| Mar 31, 2023DEF 14A | Proxy statement |
| Feb 15, 202310-K | Annual report, FY2022 — revenue $156.59B (+13% y/y), net income $5.89B, EPS $24.28 |
13 current reports (8-K) not listed; the year is on EDGAR.
2022 · 20 filings — 11 × 8-K, 3 × 10-Q, 2 × DEFA14A and 4 other forms
| Filed | What it is |
|---|---|
| Oct 19, 202210-Q | Quarterly report, Q3 2022 — revenue $39.94B (+11% y/y), net income $1.60B, EPS $6.62 |
| Jul 20, 202210-Q | Quarterly report, Q2 2022 — revenue $38.63B (+14% y/y), net income $1.64B, EPS $6.73 |
| May 6, 2022DEFA14A | Additional proxy materials |
| Apr 20, 202210-Q | Quarterly report, Q1 2022 — revenue $38.09B (+18% y/y), net income $1.79B, EPS $7.32 |
| Apr 1, 2022DEFA14A | Additional proxy materials |
| Apr 1, 2022DEF 14A | Proxy statement |
| Mar 11, 2022PRE 14A | Preliminary proxy statement |
| Feb 16, 202210-K | Annual report, FY2021 — revenue $138.64B (+14% y/y), net income $6.16B, EPS $24.95 |
12 current reports (8-K) not listed; the year is on EDGAR.
2021 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Oct 20, 202110-Q | Quarterly report, Q3 2021 — revenue $35.82B (+15% y/y), net income $1.51B, EPS $6.13 |
| Jul 21, 202110-Q | Quarterly report, Q2 2021 — revenue $33.85B (+16% y/y), net income $1.79B, EPS $7.25 |
| Apr 21, 202110-Q | Quarterly report, Q1 2021 — revenue $32.38B (+9% y/y), net income $1.67B, EPS $6.71 |
| Apr 9, 2021DEFA14A | Additional proxy materials |
| Apr 9, 2021DEF 14A | Proxy statement |
| Feb 18, 202110-K | Annual report, FY2020 — revenue $121.87B (+17% y/y), net income $4.57B, EPS $17.98 |
10 current reports (8-K) not listed; the year is on EDGAR.
2020 · 17 filings — 10 × 8-K, 3 × 10-Q, 2 × DEFA14A and 2 other forms
| Filed | What it is |
|---|---|
| Oct 28, 202010-Q | Quarterly report, Q3 2020 — revenue $31.16B (+17% y/y), net income $222.0M, EPS $0.87 |
| Jul 29, 202010-Q | Quarterly report, Q2 2020 — revenue $29.26B (+15% y/y), net income $2.28B, EPS $8.91 |
| Apr 29, 202010-Q | Quarterly report, Q1 2020 — revenue $29.62B (+20% y/y), net income $1.52B, EPS $5.94 |
| Apr 17, 2020DEFA14A | Additional proxy materials |
| Mar 27, 2020DEFA14A | Additional proxy materials |
| Mar 27, 2020DEF 14A | Proxy statement |
| Feb 19, 202010-K | Annual report, FY2019 — revenue $104.21B (+13% y/y), net income $4.81B, EPS $18.47 |
10 current reports (8-K) not listed; the year is on EDGAR.
2019 · 18 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
| Filed | What it is |
|---|---|
| Oct 23, 201910-Q | Quarterly report, Q3 2019 — revenue $26.67B (+15% y/y), net income $1.18B, EPS $4.55 |
| Jul 24, 201910-Q | Quarterly report, Q2 2019 — revenue $25.47B (+11% y/y), net income $1.14B, EPS $4.36 |
| Apr 24, 201910-Q | Quarterly report, Q1 2019 — revenue $24.67B (+9% y/y), net income $1.55B, EPS $5.91 |
| Mar 29, 2019DEFA14A | Additional proxy materials |
| Mar 29, 2019DEF 14A | Proxy statement |
| Mar 14, 2019PRE 14A | Preliminary proxy statement |
| Feb 20, 201910-K | Annual report, FY2018 — revenue $92.11B (+2% y/y), net income $3.75B, EPS $14.19 |
11 current reports (8-K) not listed; the year is on EDGAR.
2018 · 18 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Oct 31, 201810-Q | Quarterly report, Q3 2018 — revenue $23.25B (+4% y/y), net income $960.0M, EPS $3.62 |
| Jul 25, 201810-Q | Quarterly report, Q2 2018 — revenue $22.94B (+2% y/y), net income $1.05B, EPS $3.98 |
| Apr 25, 201810-Q | Quarterly report, Q1 2018 — revenue $22.54B (+0% y/y), net income $1.31B, EPS $4.99 |
| Apr 2, 2018DEFA14A | Additional proxy materials |
| Apr 2, 2018DEF 14A | Proxy statement |
| Mar 9, 2018PRE 14A | Preliminary proxy statement |
| Feb 21, 201810-K | Annual report, FY2017 — revenue $90.04B (+6% y/y), net income $3.84B, EPS $14.35 |
11 current reports (8-K) not listed; the year is on EDGAR.
2017 · 27 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Oct 25, 201710-Q | Quarterly report, Q3 2017 — revenue $22.43B (+5% y/y), net income $747.0M, EPS $2.80 |
| Jul 26, 201710-Q | Quarterly report, Q2 2017 — revenue $22.41B (+4% y/y), net income $855.0M, EPS $3.16 |
| Apr 26, 201710-Q | Quarterly report, Q1 2017 — revenue $22.52B (+11% y/y), net income $1.01B, EPS $3.73 |
| Mar 31, 2017DEFA14A | Additional proxy materials |
| Mar 31, 2017DEF 14A | Proxy statement |
| Mar 10, 2017PRE 14A | Preliminary proxy statement |
| Feb 22, 201710-K | Annual report, FY2016 — revenue $84.86B (+7% y/y), net income $2.47B, EPS $9.21 |
20 current reports (8-K) not listed; the year is on EDGAR.
2016 · 19 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2015 · 23 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2014 · 27 filings — 17 × 8-K, 3 × 10-Q, 2 × DEF 14A and 4 other forms
Counted, not listed; the year is on EDGAR.
2013 · 29 filings — 21 × 8-K, 3 × 10-Q, 2 × DEFA14A and 3 other forms
Counted, not listed; the year is on EDGAR.
2012 · 35 filings — 23 × 8-K, 3 × 10-Q, 3 × DEFA14A and 4 other forms
Counted, not listed; the year is on EDGAR.
2011 · 26 filings — 17 × 8-K, 3 × 10-Q, 2 × DEFA14A and 4 other forms
Counted, not listed; the year is on EDGAR.
2010 · 25 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2009 · 23 filings — 16 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2008 · 20 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2007 · 26 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2006 · 24 filings — 17 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2005 · 25 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
Counted, not listed; the year is on EDGAR.
2004 · 28 filings — 20 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
Counted, not listed; the year is on EDGAR.
2003 · 21 filings — 15 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
Counted, not listed; the year is on EDGAR.
2002 · 27 filings — 21 × 8-K, 3 × 10-Q, 1 × 10-K405 and 2 other forms
Counted, not listed; the year is on EDGAR.
2001 · 3 filings — 2 × 8-K, 1 × 10-Q
Counted, not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 42 filings — 32 × 4, 5 × 144, 2 × 11-K and 3 other forms
| Filed | What it is |
|---|---|
| Oct 6, 20264 | Insider transaction (Form 4) |
| Sep 4, 20264 | Insider transaction (Form 4) |
| Sep 4, 20264 | Insider transaction (Form 4) |
| Jul 17, 20264 | Insider transaction (Form 4) |
| Jul 17, 20264 | Insider transaction (Form 4) |
| Jul 7, 2026144 | Notice of proposed sale (Form 144) |
| Jun 17, 202611-K | Employee plan annual report |
| Jun 17, 202611-K | Employee plan annual report |
| Jun 15, 20264 | Insider transaction (Form 4) |
| Jun 12, 2026144 | Notice of proposed sale (Form 144) |
| Jun 12, 20264 | Insider transaction (Form 4) |
| Jun 11, 2026144 | Notice of proposed sale (Form 144) |
| May 20, 20264 | Insider transaction (Form 4) |
| May 19, 2026144 | Notice of proposed sale (Form 144) |
| May 15, 20264 | Insider transaction (Form 4) |
| May 15, 20264 | Insider transaction (Form 4) |
| May 15, 20264 | Insider transaction (Form 4) |
| May 15, 20264 | Insider transaction (Form 4) |
| May 15, 20264 | Insider transaction (Form 4) |
| May 15, 20264 | Insider transaction (Form 4) |
| May 15, 20264 | Insider transaction (Form 4) |
| May 15, 20264 | Insider transaction (Form 4) |
| May 15, 20264 | Insider transaction (Form 4) |
| May 15, 20264 | Insider transaction (Form 4) |
| Apr 29, 2026SCHEDULE 13G | Other filings |
The newest 25 of 42 shown; the full year is on EDGAR.
2025 · 40 filings — 26 × 4, 3 × 144, 3 × 3 and 5 other forms
| Filed | What it is |
|---|---|
| Nov 21, 20253/A | Initial insider holdings (Form 3), amended |
| Oct 3, 20254 | Insider transaction (Form 4) |
| Sep 9, 2025424B3 | Prospectus |
| Sep 8, 2025FWP | Free writing prospectus |
| Sep 8, 2025424B3 | Prospectus |
| Sep 5, 20254 | Insider transaction (Form 4) |
| Sep 5, 20253 | Initial insider holdings (Form 3) |
| Sep 5, 20253 | Initial insider holdings (Form 3) |
| Sep 4, 20254 | Insider transaction (Form 4) |
| Sep 4, 20254 | Insider transaction (Form 4) |
| Aug 21, 20254 | Insider transaction (Form 4) |
| Aug 5, 20254 | Insider transaction (Form 4) |
| Aug 1, 20253 | Initial insider holdings (Form 3) |
| Jul 18, 20254 | Insider transaction (Form 4) |
| Jun 24, 202511-K | Employee plan annual report |
| Jun 24, 202511-K | Employee plan annual report |
| May 16, 20254 | Insider transaction (Form 4) |
| May 16, 20254 | Insider transaction (Form 4) |
| May 16, 20254 | Insider transaction (Form 4) |
| May 16, 20254 | Insider transaction (Form 4) |
| May 16, 20254 | Insider transaction (Form 4) |
| May 16, 20254 | Insider transaction (Form 4) |
| May 16, 20254 | Insider transaction (Form 4) |
| May 16, 20254 | Insider transaction (Form 4) |
| May 16, 20254 | Insider transaction (Form 4) |
The newest 25 of 40 shown; the full year is on EDGAR.
2024 · 52 filings — 30 × 4, 9 × 144, 4 × 424B3 and 6 other forms
| Filed | What it is |
|---|---|
| Nov 14, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 5, 20244 | Insider transaction (Form 4) |
| Nov 5, 20244 | Insider transaction (Form 4) |
| Oct 23, 2024424B3 | Prospectus |
| Oct 22, 2024FWP | Free writing prospectus |
| Oct 22, 2024424B3 | Prospectus |
| Oct 18, 20244 | Insider transaction (Form 4) |
| Oct 18, 2024144 | Notice of proposed sale (Form 144) |
| Oct 4, 20244 | Insider transaction (Form 4) |
| Aug 6, 20244 | Insider transaction (Form 4) |
| Aug 5, 2024144 | Notice of proposed sale (Form 144) |
| Jul 23, 20244 | Insider transaction (Form 4) |
| Jul 22, 20244 | Insider transaction (Form 4) |
| Jul 22, 2024144 | Notice of proposed sale (Form 144) |
| Jul 19, 2024144 | Notice of proposed sale (Form 144) |
| Jun 20, 202411-K | Employee plan annual report |
| May 21, 2024424B3 | Prospectus |
| May 20, 2024FWP | Free writing prospectus |
| May 20, 2024424B3 | Prospectus |
| May 17, 20244 | Insider transaction (Form 4) |
| May 17, 20244 | Insider transaction (Form 4) |
| May 17, 20244 | Insider transaction (Form 4) |
| May 17, 20244 | Insider transaction (Form 4) |
| May 17, 20244 | Insider transaction (Form 4) |
| May 17, 20244 | Insider transaction (Form 4) |
The newest 25 of 52 shown; the full year is on EDGAR.
2023 · 43 filings — 30 × 4, 3 × 144, 3 × SC 13G/A and 6 other forms
Counted, not listed; the year is on EDGAR.
2022 · 40 filings — 28 × 4, 4 × 424B3, 2 × FWP and 4 other forms
Counted, not listed; the year is on EDGAR.
2021 · 48 filings — 39 × 4, 3 × SC 13G/A, 2 × 3 and 3 other forms
Counted, not listed; the year is on EDGAR.
2020 · 56 filings — 45 × 4, 4 × SC 13G/A, 2 × 3 and 4 other forms
Counted, not listed; the year is on EDGAR.
2019 · 47 filings — 36 × 4, 4 × SC 13G/A, 2 × 3 and 5 other forms
Counted, not listed; the year is on EDGAR.
2018 · 58 filings — 47 × 4, 3 × 3, 3 × SC 13G/A and 5 other forms
Counted, not listed; the year is on EDGAR.
2017 · 67 filings — 45 × 4, 4 × 425, 3 × 3 and 11 other forms
Counted, not listed; the year is on EDGAR.
2016 · 75 filings — 57 × 4, 11 × 425, 3 × SC 13G/A and 3 other forms
Counted, not listed; the year is on EDGAR.
2015 · 105 filings — 42 × 425, 38 × 4, 3 × 3 and 15 other forms
Counted, not listed; the year is on EDGAR.
2014 · 56 filings — 43 × 4, 4 × 3, 1 × 11-K and 8 other forms
Counted, not listed; the year is on EDGAR.
2013 · 68 filings — 52 × 4, 6 × 3, 2 × UPLOAD and 8 other forms
Counted, not listed; the year is on EDGAR.
2012 · 67 filings — 50 × 4, 3 × 3, 2 × 424B5 and 8 other forms
Counted, not listed; the year is on EDGAR.
2011 · 68 filings — 52 × 4, 3 × 3, 2 × NO ACT and 10 other forms
Counted, not listed; the year is on EDGAR.
2010 · 87 filings — 78 × 4, 2 × SC 13G/A, 2 × UPLOAD and 5 other forms
Counted, not listed; the year is on EDGAR.
2009 · 85 filings — 71 × 4, 3 × UPLOAD, 2 × CORRESP and 7 other forms
Counted, not listed; the year is on EDGAR.
2008 · 103 filings — 86 × 4, 5 × 3, 3 × CORRESP and 6 other forms
Counted, not listed; the year is on EDGAR.
2007 · 146 filings — 127 × 4, 6 × 3, 4 × CORRESP and 6 other forms
Counted, not listed; the year is on EDGAR.
2006 · 194 filings — 155 × 4, 21 × 4/A, 2 × 3 and 12 other forms
Counted, not listed; the year is on EDGAR.
2005 · 147 filings — 115 × 4, 7 × 425, 3 × 3 and 13 other forms
Counted, not listed; the year is on EDGAR.
2004 · 216 filings — 163 × 4, 19 × 3, 17 × 425 and 8 other forms
Counted, not listed; the year is on EDGAR.
2003 · 101 filings — 81 × 4, 15 × 425, 2 × 11-K and 3 other forms
Counted, not listed; the year is on EDGAR.
2002 · 28 filings — 18 × 425, 4 × S-8, 1 × 424B4 and 5 other forms
Counted, not listed; the year is on EDGAR.
2001 · 13 filings — 5 × S-1/A, 2 × 424B4, 2 × 8-A12B and 3 other forms
Counted, not listed; the year is on EDGAR.
About this data#
Elevance Health Inc. (ELV) has 2,624 filings on EDGAR going back to 2001: 25 annual reports, 78 quarterly reports and 390 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 6, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Oct 21, 2026, furnished a press release headed “ELEVANCE HEALTH REPORTS THIRD QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCE”. Over the last 13 months insiders sold $1.7M in 5 sales and bought $2.2M in 3 purchases; 53 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been Elevance Health Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read ELV's latest 10-K?
- ELV's latest annual report, a 10-K, was filed on Feb 6, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did ELV last file an 8-K?
- On Oct 21, 2026 it furnished a press release headed “ELEVANCE HEALTH REPORTS THIRD QUARTER 2026 RESULTS; RAISES FULL-YEAR GUIDANCE”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Oct 21, 2026.
- Are ELV insiders buying or selling?
- Over the last 13 months insiders sold $1.7M in 5 sales and bought $2.2M in 3 purchases; 53 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Penczek Ronald W (CAO & Controller) sold 369 shares on Jun 12, 2026 for $149K. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has ELV made?
- 2,624 filings are on EDGAR under the registrant records that have been Elevance Health Inc., going back to 2001; 1,661 of them are insider ownership forms (Forms 3, 4, 5 and 144).